Immune cell profiling is crucial towards understanding key changes in host immune cell subpopulations and functions underlying SARS-CoV-2 viral clearance and immune-mediated pathology. This data will be essential towards the urgent development of COVID-19 diagnostics, therapeutics, and vaccines. Recent publications have showcased the power of scRNA-Seq immune cell profiling to dissect complex host immune response to SARS- CoV-2 infections. These published studies have pointed to subtle changes in key immune cell subsets, and RNA expression of pro-inflammatory cytokines and other targets, correlated to disease severity and treatment response, that would have been missed with bulk sample analysis. However, most scRNA-Seq studies are limited in patient sampling statistics given the cost and complexity of next-generation sequencing. In order to orthogonally validate scRNA-Seq discoveries, and significantly expand study sizes to include more patients and/or increase longitudinal monitoring timepoints during disease progression, resolution, and treatment, single- cell targeted RNA detection approaches with orders of magnitude higher throughput and lower cost are needed. Established single-cell techniques such as flow cytometry (and more recently mass cytometry) are complementary tools that can scale the number of samples and single cells analyzed across a subset of targets identified by scRNA-Seq. However, these platforms are largely restricted to detection of proteins via antibody- based reagents. Often, the RNA targets identified by scRNA-Seq may not code for proteins with existing flow cytometry-validated antibodies or may be non-coding transcripts. We propose to develop highly multiplexed (>15 RNA targets), fast (<4 hours) and sensitive CRISPR-based RNA detection kits compatible with flow and mass cytometry analysis. While Cas9 is best known as a programmable sequence-specific DNA endonuclease for gene editing applications, Cas9 can be re-directed to bind and cut RNA by hybridization of a protospacer- adjacent motif (PAM; a sequence required for Cas9 DNA cleavage)-containing DNA oligonucleotide (a PAMmer) to the target RNA (RCas9). The objective of this Phase I STTR project is to demonstrate detection of IFNG mRNA in fixed and permeabilized T cells with flow cytometry. The project is organized in two aims to first improve S/N of Cas9 nucleic acid binding proteins by engineering novel multi-epitope tagged proteins to increase fluorescent secondary antibody labeling sites (Aim 1), then test multiple guideRNA and PAMmer designs targeting the length of IFNG mRNA in fixed and permeabilized cells via fluorescence imaging and flow cytometry (Aim 2). Commercialization of Dahlia Biosciences RNA detection reagent kits compatible with both fluorescence and metal ion tag detection systems will address a critical gap for in situ RNA detection tools across multiple fields, including infectious diseases such as COVID-19. Public Health Relevance Statement Project Narrative Understanding host immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection is critical towards formulating strategies aimed at the prevention, diagnosis and treatment of COVID-19 disease. We propose to develop robust and easy-to-use reagent kits to enable scientists to profile key immune cell RNA targets via flow and mass cytometry.
Project Terms: immune system response ; immunoresponse ; Immune response ; Therapeutic ; Inflammatory ; tool ; scaffolding ; scaffold ; programs ; Scientist ; Hour ; Immunes ; Immune ; Complex ; In Situ ; Dahlia ; Pattern ; Techniques ; System ; Viral ; disease severity ; Severity of illness ; single cell analysis ; fluorophore ; antibody conjugate ; nucleic acid binding protein ; novel ; Prevention ; Cytometry ; Sampling ; nucleic acid detection ; Functional RNA ; Non-Coding ; Non-Coding RNA ; Non-translated RNA ; Noncoding RNA ; Nontranslated RNA ; noncoding ; Untranslated RNA ; Bio-Informatics ; Bioinformatics ; Molecular Interaction ; Binding ; Address ; Length ; Data ; Detection ; Qualifying ; Reproducibility ; Resolution ; mRNA Expression ; Small Business Technology Transfer Research ; STTR ; Transcript ; Monitor ; Development ; developmental ; Image ; imaging ; cost ; multiplex detection ; design ; designing ; Consumption ; innovation ; innovate ; innovative ; fluorescence imaging ; fluorescent imaging ; commercialization ; treatment response ; response to treatment ; therapeutic response ; next generation sequencing ; NGS Method ; NGS system ; next gen sequencing ; nextgen sequencing ; Clustered Regularly Interspaced Short Palindromic Repeats ; CRISPR ; CRISPR/Cas system ; transcriptome ; global gene expression ; global transcription profile ; biomarker discovery ; experimental study ; experiment ; experimental research ; single-cell RNA sequencing ; scRNA-seq ; single cell RNA-seq ; single cell RNAseq ; COVID-19 ; COVID19 ; CV-19 ; CV19 ; corona virus disease 2019 ; coronavirus disease 2019 ; 2019-nCoV ; 2019 novel corona virus ; 2019 novel coronavirus ; COVID-19 virus ; COVID19 virus ; CoV-2 ; CoV2 ; SARS corona virus 2 ; SARS-CoV-2 ; SARS-CoV2 ; SARS-associated corona virus 2 ; SARS-associated coronavirus 2 ; SARS-coronavirus-2 ; SARS-related corona virus 2 ; SARS-related coronavirus 2 ; SARSCoV2 ; Severe Acute Respiratory Distress Syndrome CoV 2 ; Severe Acute Respiratory Distress Syndrome Corona Virus 2 ; Severe Acute Respiratory Distress Syndrome Coronavirus 2 ; Severe Acute Respiratory Syndrome CoV 2 ; Severe Acute Respiratory Syndrome-associated coronavirus 2 ; Severe Acute Respiratory Syndrome-related coronavirus 2 ; Severe acute respiratory syndrome associated corona virus 2 ; Severe acute respiratory syndrome corona virus 2 ; Severe acute respiratory syndrome coronavirus 2 ; Severe acute respiratory syndrome related corona virus 2 ; Wuhan coronavirus ; coronavirus disease 2019 virus ; hCoV19 ; nCoV2 ; coronavirus disease ; COVID ; CoV disease ; corona virus disease ; COVID-19 treatment ; COVID-19 therapy ; COVID19 therapy ; COVID19 treatment ; SARS-CoV-2 therapy ; SARS-CoV-2 treatment ; coronavirus disease 2019 therapy ; coronavirus disease 2019 treatment ; severe acute respiratory syndrome coronavirus 2 therapy ; severe acute respiratory syndrome coronavirus 2 treatment ; treat COVID-19 ; treat COVID19 ; treat SARS-CoV-2 ; treat coronavirus disease 2019 ; treat severe acute respiratory syndrome coronavirus 2 ; COVID-19 diagnostic ; COVID19 diagnostic ; SARS-CoV-2 diagnostic ; coronavirus disease 2019 diagnostic ; severe acute respiratory syndrome coronavirus 2 diagnostic ; COVID-19 patient ; COVID infected patient ; COVID patient ; COVID positive patient ; COVID-19 infected patient ; COVID-19 positive patient ; COVID19 patient ; COVID19 positive patient ; SARS-CoV-2 infected patient ; SARS-CoV-2 patient ; SARS-CoV-2 positive patient ; coronavirus disease 2019 infected patient ; coronavirus disease 2019 patient ; coronavirus disease 2019 positive patient ; coronavirus disease infected patient ; coronavirus disease patient ; coronavirus disease positive patient ; coronavirus patient ; patient infected with COVID ; patient infected with COVID-19 ; patient infected with SARS-CoV-2 ; patient infected with coronavirus disease ; patient infected with coronavirus disease 2019 ; patient infected with severe acute respiratory syndrome coronavirus 2 ; patient with COVID ; patient with COVID-19 ; patient with COVID19 ; patient with SARS-CoV-2 ; patient with coronavirus disease ; patient with coronavirus disease 2019 ; patient with severe acute respiratory distress syndrome coronavirus 2 ; severe acute respiratory syndrome coronavirus 2 infected patient ; severe acute respiratory syndrome coronavirus 2 patient ; severe acute respiratory syndrome coronavirus 2 positive patient ; detection method ; detection procedure ; detection technique ; detection platform ; detection system ; SARS-CoV-2 infection ; COVID-19 infection ; COVID19 infection ; SARS-CoV2 infection ; Severe acute respiratory syndrome coronavirus 2 infection ; coronavirus disease 2019 infection ; infected with COVID-19 ; infected with COVID19 ; infected with SARS-CoV-2 ; infected with SARS-CoV2 ; infected with coronavirus disease 2019 ; infected with severe acute respiratory syndrome coronavirus 2 ; Antibodies ; Epitopes ; Antigenic Determinants ; Binding Determinants ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Biological Sciences ; Biologic Sciences ; Bioscience ; Life Sciences ; Cell Line ; CellLine ; Strains Cell Lines ; cultured cell line ; Cells ; Cell Body ; Communicable Diseases ; Infectious Disease Pathway ; Infectious Diseases ; Infectious Disorder ; Deoxyribonuclease I ; DNA Endonuclease ; DNase I ; Pancreatic DNase ; Thymonuclease ; Diagnosis ; Disease ; Disorder ; DNA ; Deoxyribonucleic Acid ; Flow Cytometry ; Flow Cytofluorometries ; Flow Cytofluorometry ; Flow Microfluorimetry ; Flow Microfluorometry ; flow cytophotometry ; Fluorescence ; Genes ; Goals ; Interferon Type II ; Gamma interferon ; IFN-Gamma ; IFN-g ; IFN-γ ; IFNG ; IFNγ ; Immune Interferon ; Interferon Gamma ; Interferon-gamma ; lFN-Gamma ; Ions ; Libraries ; Masks ; Metals ; Noise ; Oligonucleotides ; Oligo ; oligos ; Pathology ; Patients ; Protein Engineering ; genetic protein engineering ; protein design ; Proteins ; Publications ; Scientific Publication ; Publishing ; Reagent ; Research Personnel ; Investigators ; Researchers ; RNA ; Non-Polyadenylated RNA ; RNA Gene Products ; Ribonucleic Acid ; Messenger RNA ; mRNA ; Signal Transduction ; Cell Communication and Signaling ; Cell Signaling ; Intracellular Communication and Signaling ; Signal Transduction Systems ; Signaling ; biological signal transduction ; Specificity ; Stains ; Staining method ; statistics ; T-Lymphocyte ; T-Cells ; thymus derived lymphocyte ; Technology ; Testing ; Time ; Vaccines ; Virus Diseases ; Viral Diseases ; viral infection ; virus infection ; virus-induced disease ; cytokine ; Guide RNA ; gRNA ; telomere ; Immune Response Genes ; Ir Gene ; Mediating ; Chimeric Proteins ; Chimera Protein ; Fusion Protein ; base ; Label ; improved ; Site ; Phase ; Individual ; Disease Progression ; Image Cytometry ; Immunological response ; host response ;
